Adverse events as predictive indicators of treatment efficacy in HCC

Mara Persano, University Hospital of Cagliari, Italy, discusses the potential of adverse events as predictive factors of treatment efficacy in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab. Similar to the observed effects with tyrosine kinase inhibitors (TKIs), adverse events like arterial hypertension may serve as indicators of therapeutic activity. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.